Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marsiglio

Showing results (131-140 of 140) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 140 results.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|April 22, 2021
A survey of the prevalence, management and outcome of infants with an inconclusive diagnosis following newborn bloodspot screening for cystic fibrosis (CRMS/CFSPID) in six Italian centresVito Terlizzi, Laura Claut, Antonella Tosco, et al.
Bioorganic & Medicinal Chemistry|October 22, 2013
Discovery and optimization of pyrrolo[1,2-a]pyrazinones leads to novel and selective inhibitors of PIM kinasesFrancesco Casuscelli, Elena Ardini, Nilla Avanzi, et al.
Molecular Cancer Therapeutics|December 20, 2007
PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancerPatrizia Carpinelli, Roberta Ceruti, Maria Laura Giorgini, et al.
Journal of Medicinal Chemistry|April 15, 2005
3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 2. Lead optimizationPaolo Pevarello, Maria Gabriella Brasca, Paolo Orsini, et al.
Journal of Medicinal Chemistry|April 15, 2005
Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibitionDaniele Fancelli, Daniela Berta, Simona Bindi, et al.
Journal of Medicinal Chemistry|November 28, 2006
1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profileDaniele Fancelli, Jürgen Moll, Mario Varasi, et al.
Journal for Immunotherapy of Cancer|January 17, 2024
Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4<sup>+</sup> naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanomaMagdalena Kovacsovics-Bankowski, Johanna M Sweere, Connor P Healy, et al.
Bioorganic & Medicinal Chemistry|September 7, 2010
Thieno[3,2-c]pyrazoles: a novel class of Aurora inhibitors with favorable antitumor activitySimona Bindi, Daniele Fancelli, Cristina Alli, et al.
Journal of Medicinal Chemistry|June 11, 2004
3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead findingPaolo Pevarello, Maria Gabriella Brasca, Raffaella Amici, et al.
European Journal of Cancer (Oxford, England : 1990)|October 4, 2024
Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapyRachel Woodford, Janet McKeown, Lotte L Hoeijmakers, et al.
Pageof 14

Showing results (131-140 of 140) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 140 results.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|April 22, 2021
A survey of the prevalence, management and outcome of infants with an inconclusive diagnosis following newborn bloodspot screening for cystic fibrosis (CRMS/CFSPID) in six Italian centresVito Terlizzi, Laura Claut, Antonella Tosco, et al.
Bioorganic & Medicinal Chemistry|October 22, 2013
Discovery and optimization of pyrrolo[1,2-a]pyrazinones leads to novel and selective inhibitors of PIM kinasesFrancesco Casuscelli, Elena Ardini, Nilla Avanzi, et al.
Molecular Cancer Therapeutics|December 20, 2007
PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancerPatrizia Carpinelli, Roberta Ceruti, Maria Laura Giorgini, et al.
Journal of Medicinal Chemistry|April 15, 2005
3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 2. Lead optimizationPaolo Pevarello, Maria Gabriella Brasca, Paolo Orsini, et al.
Journal of Medicinal Chemistry|April 15, 2005
Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibitionDaniele Fancelli, Daniela Berta, Simona Bindi, et al.
Journal of Medicinal Chemistry|November 28, 2006
1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profileDaniele Fancelli, Jürgen Moll, Mario Varasi, et al.
Journal for Immunotherapy of Cancer|January 17, 2024
Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4<sup>+</sup> naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanomaMagdalena Kovacsovics-Bankowski, Johanna M Sweere, Connor P Healy, et al.
Bioorganic & Medicinal Chemistry|September 7, 2010
Thieno[3,2-c]pyrazoles: a novel class of Aurora inhibitors with favorable antitumor activitySimona Bindi, Daniele Fancelli, Cristina Alli, et al.
Journal of Medicinal Chemistry|June 11, 2004
3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead findingPaolo Pevarello, Maria Gabriella Brasca, Raffaella Amici, et al.
European Journal of Cancer (Oxford, England : 1990)|October 4, 2024
Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapyRachel Woodford, Janet McKeown, Lotte L Hoeijmakers, et al.
Pageof 14